EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Diagnostic and Prognostic Value of hsa_piR_022710, hsa_piR_019822, and hsa_piR_020840 in Early-Stage Non-Small-Cell Lung Cancer: Implications for Recurrence and Survival in Squamous Cell Carcinoma Patients

Yangyi He, Antonio Altuna-Coy iD, Melissa Acosta-Plasencia, Laureano Molins iD, David Sánchez-Lorente iD, Daniel Martinez iD, Tania Díaz, Risha Na, Ramón M Marrades, Alfons Navarro iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26072870 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Yangyi He und 9 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Oncology and Embryology Laboratory, Human Anatomy and Embryology Unit, Department of Surgery and Medical-Surgical Specialties, Faculty of M…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sociedad Española de Neumología y Cirugía Torácica, Agencia Estatal de Investigación, Ministry of Economy and Competition (MINECO).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite significant advancements in early detection and treatment, non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality. Specifically, in early-stage cases, recurrence after surgery continues to be the principal cause of death for these patients. The urgent need for novel diagnostic and prognostic biomarkers has directed attention towards PIWI-interacting RNAs (piRNAs), a group of small RNAs that regulate genomic stability and epigenetics. Some piRNAs, including hsa_piR_022710, hsa_piR_019822, and hsa_piR_020840, have been described as deregulated in various cancers. This study investigated the expression of these three piRNAs by RT-qPCR in 277 NSCLC patients and developed survival and CART classification models to predict recurrence risk, overall survival (OS), and disease-free survival (DFS). hsa_piR_019822 and hsa_piR_020840 were able to discriminate between tumor and normal tissue, as well as between adenocarcinoma and squamous cell carcinoma (LUSC) patients. Elevated expression of hsa_piR_019822 and hsa_piR_022710 was correlated with an increased risk of recurrence and poorer DFS and OS in LUSC patients. Patients with high hsa_piR_022710 expression more greatly benefited from adjuvant treatment. In summary, higher piRNA levels were associated with an increased risk of recurrence and poorer survival outcomes, especially in LUSC patients, where they may help guide personalized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCarcinoma, Squamous CellNeoplasm Recurrence, LocalBiomarkers, TumorRNA, Small InterferingHumansMaleFemaleMiddle AgedPrognosisAgedNeoplasm StagingGene Expression Regulation, NeoplasticAdultDisease-Free Survival

Stichwörter der Autor:innen

NSCLCbiomarkerspiRNAprognosisrecurrencesquamous cell carcinoma

Substanzen

Biomarkers, TumorRNA, Small Interfering

Autor:innen und Institutionen

  • Molecular Oncology and Embryology Laboratory, Human Anatomy and Embryology Unit, Department of Surgery and Medical-Surgical Specialties, Faculty of Medicine and Health Sciences, Universitat de Barcelona (UB), c. Casanov…
  • School of Basic Medical Sciences, Chengdu University, Chengdu 610106, China.
  • Department of Thoracic Surgery, Hospital Clínic de Barcelona, Universitat de Barcelona (UB), 08036 Barcelona, Spain.
  • Thoracic Oncology Unit, Hospital Clínic de Barcelona, Universitat de Barcelona (UB), 08036 Barcelona, Spain.
  • Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), c. Villarroel 170, 08036 Barcelona, Spain.
  • Department of Thoracic Surgery, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT), Universitat Autònoma de Barcelona, 08202 Sabadell, Spain.

ORCID-Profile: Antonio Altuna-Coy, Laureano Molins, David Sánchez-Lorente, Daniel Martinez, Alfons Navarro

Förderung

  • Sociedad Española de Neumología y Cirugía Torácica
  • Agencia Estatal de Investigación
  • Ministry of Economy and Competition (MINECO)
  • SEPAR-AstraZeneca Ayudas Investigación PII Oncología 2021
  • Becas SEPAR 2022
  • Becas SEPAR 2023

Zitieren

APA

He, Y., Altuna-Coy, A., Acosta-Plasencia, M., Molins, L., Sánchez-Lorente, D., Martinez, D., Díaz, T., Na, R., Marrades, R. M., & Navarro, A. (2025). Diagnostic and Prognostic Value of hsa_piR_022710, hsa_piR_019822, and hsa_piR_020840 in Early-Stage Non-Small-Cell Lung Cancer: Implications for Recurrence and Survival in Squamous Cell Carcinoma Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26072870

Vancouver

He Y, Altuna-Coy A, Acosta-Plasencia M, Molins L, Sánchez-Lorente D, Martinez D, et al. Diagnostic and Prognostic Value of hsa_piR_022710, hsa_piR_019822, and hsa_piR_020840 in Early-Stage Non-Small-Cell Lung Cancer: Implications for Recurrence and Survival in Squamous Cell Carcinoma Patients. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26072870

BibTeX
@article{He2025,
  author = {He, Yangyi and Altuna-Coy, Antonio and Acosta-Plasencia, Melissa and Molins, Laureano and Sánchez-Lorente, David and Martinez, Daniel and Díaz, Tania and Na, Risha and Marrades, Ramón M and Navarro, Alfons},
  title = {Diagnostic and Prognostic Value of hsa_piR_022710, hsa_piR_019822, and hsa_piR_020840 in Early-Stage Non-Small-Cell Lung Cancer: Implications for Recurrence and Survival in Squamous Cell Carcinoma Patients},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26072870}
}
Kostenlos starten →